Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc Ltd. (NASDAQ: SPRC) announced the closure of a private placement, securing approximately $10 million in gross proceeds from a single healthcare-focused institutional investor. The company issued 3,546,100 units at a price of $2.82 per unit, consisting of one ordinary share and two non-tradable warrants, each exercisable for an ordinary share at $2.57 for a total of 7,092,200 shares underlying the warrants. The warrants have a term of five years. Aegis Capital Corp. acted as the exclusive placement agent.
SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Polyrizon Ltd. to develop an innovative pain treatment using SciSparc's SCI-160 platform combined with Polyrizon's Trap and TargetTM technology. The goal is to create a proprietary intranasal formulation that maintains effective SCI-160 concentrations in the brain. SciSparc will pay up to $2,550,000 in development fees, plus royalties on product sales. Previous pre-clinical trials demonstrated SCI-160's efficacy and safety in pain management, with results comparable to high-dose morphine.
SciSparc Ltd. (NASDAQ: SPRC) announced a securities purchase agreement with a healthcare-focused investor, generating approximately $10 million in gross proceeds. The offering includes the issuance of 3,546,100 units, priced at $2.82 each, consisting of ordinary shares and warrants exercisable at $2.57. The transaction is set to close on or around June 1, 2022. Aegis Capital is the exclusive placement agent. The securities are being sold in a private placement and won't be registered under the Securities Act of 1933, requiring compliance with SEC regulations.
SciSparc Ltd. (NASDAQ: SPRC) has received Ethics Committee approvals for its Phase IIb clinical trial of SCI-110 targeting Tourette Syndrome (TS) at Hannover Medical School and Tel Aviv Sourasky Medical Center. This phase aims to assess the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65, using the Yale Global Tic Severity Scale for measuring tic severity over 12 and 26 weeks. While the trial awaits health ministry approvals, the company continues to identify additional clinical sites to expedite patient enrollment. Positive results from earlier studies at Yale University encourage further development.
SciSparc Ltd. (NASDAQ: SPRC) announced positive results from a joint pre-clinical trial with Clearmind Medicine Inc. The trial evaluated the safety of SciSparc's CannAmide™ and Clearmind's psychedelic molecule MEAI for reducing alcohol consumption.
Findings showed high safety with no treatment-related changes across various organs. Significant reductions in alcohol intake were observed with MEAI at 40 mg/kg and lower doses combined with CannAmide™.
The company aims to further investigate the safety and efficacy of this novel treatment.
On May 10, 2022, SciSparc Ltd. (NASDAQ: SPRC) announced promising preclinical results from its collaboration with Clearmind Medicine Inc. The combination of SciSparc's CannAmide™ and Clearmind's MEAI has shown potential in significantly reducing alcohol consumption in treated animals. The collaboration led to a provisional patent application for this psychedelic combination therapy. Initial studies indicated a dose-dependent effect, with alcohol intake reduced by 40 mg/kg MEAI and dual treatment with 25 mg/kg CannAmide™. The company aims to strengthen its IP portfolio in the psychedelic sector.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical firm, filed its annual report on Form 20-F for the fiscal year 2021 with the SEC on May 2, 2022. Key achievements include the issuance of a U.S. patent for its technology targeting central nervous system disorders, recruitment of the first patient for a Phase IIa trial of SCI-110 in Alzheimer's, and progress in a Phase IIb trial for Tourette syndrome. The company also formed collaborations to develop psychedelic-based pharmaceuticals and entered a joint venture focused on drug discovery for cancer and infectious diseases.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, announced the completion of a joint venture agreement with MitoCareX Bio Ltd. to develop therapies targeting cancer and life-threatening conditions. SciSparc invested $700,000 of a planned $1.7 million, aiming for 50.01% ownership. MitoCareX will explore mitochondrial carriers, crucial for cell viability, to address various health issues. The development builds on successful trials in the UK. This strategic move reflects SciSparc's commitment to enhancing its portfolio in cannabinoid pharmaceuticals and addressing central nervous system disorders.
SciSparc Ltd. (NASDAQ: SPRC) has appointed Prof. Avi Schroeder to its Scientific Advisory Board to enhance the formulation development of its investigational pain treatment, SCI-160. The drug has shown positive results in pre-clinical trials for both acute and chronic pain. Prof. Schroeder brings extensive experience in targeted drug delivery and has made significant contributions to nanotechnology and medicine. The company plans to initiate the Pre-IND process later this year, aiming for an FDA IND Phase I study application.
SciSparc Ltd. (NASDAQ: SPRC) announced the formation of a joint venture, MitoCareX Bio Ltd., to focus on discovering and developing drugs for cancer and other serious conditions. The new Israeli-based company will explore the role of mitochondrial carriers in treating life-threatening diseases. SciSparc plans to invest up to $1.7 million over two years for a 50.01% stake, contingent on specific milestones. The initiative aims to leverage advanced drug discovery techniques and prior successful experiments in the UK, with expert Professor Ciro Leonardo Pierri advising the program.